Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
1978 1
1980 1
1983 1
1984 3
1985 2
1988 1
1989 1
1990 2
1991 3
1992 3
1993 5
1994 5
1995 6
1996 5
1997 4
1998 6
2000 6
2001 5
2002 4
2003 3
2004 4
2005 7
2006 5
2007 5
2008 4
2009 6
2010 7
2011 6
2012 9
2013 8
2014 14
2015 6
2016 9
2017 9
2018 14
2019 15
2020 11
2021 11
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

208 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Among authors: feeney a. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Among authors: feeney a. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG, Ganesan R, Wilkinson N, Perren T, Montes A, Summers J, Lord R, Dark G, Rustin G, Mackean M, Reed N, Kehoe S, Frumovitz M, Christensen H, Feeney A, Ledermann J, Gershenson DM. Gore M, et al. Among authors: feeney a. Gynecol Oncol. 2019 Jun;153(3):541-548. doi: 10.1016/j.ygyno.2019.03.256. Epub 2019 Apr 18. Gynecol Oncol. 2019. PMID: 31005287 Free PMC article. Clinical Trial.
Editorial overview. Lymphocyte development.
Corcoran AE, Feeney AJ. Corcoran AE, et al. Among authors: feeney aj. Curr Opin Immunol. 2012 Apr;24(2):129-31. doi: 10.1016/j.coi.2012.03.003. Epub 2012 Mar 20. Curr Opin Immunol. 2012. PMID: 22440337 No abstract available.
Acinetobacter baumannii: an emerging opportunistic pathogen.
Howard A, O'Donoghue M, Feeney A, Sleator RD. Howard A, et al. Among authors: feeney a. Virulence. 2012 May 1;3(3):243-50. doi: 10.4161/viru.19700. Epub 2012 May 1. Virulence. 2012. PMID: 22546906 Free PMC article. Review.
208 results